Products Categories
| CAS No.: | 60-32-2 |
|---|---|
| Name: | Hexanoicacid, 6-amino- |
| Article Data: | 115 |
| Cas Database | |
| Molecular Structure: | |
|
|
|
| Formula: | C6H13NO2 |
| Molecular Weight: | 131.175 |
| Synonyms: | Caproicacid, e-amino- (3CI);6-Amino-n-hexanoic acid;6-Aminocaproic acid;6-Aminohexanoic acid;ACS;Acepramin;Amicar;Amikar;CL10304;CY 116;Caplamin;Capramol;Caprolisin;EACA;Epsamon;Epsicapron;Epsilon S;Hemocaprol;Hemopar;Hepin;NSC 212532;NSC 26154;NSC 400230;e-Amino-n-hexanoic acid;e-Aminocaproic acid;e-Leucine;e-Norleucine;w-Aminocaproic acid;w-Aminohexanoic acid; |
| EINECS: | 200-469-3 |
| Density: | 1.042 g/cm3 |
| Melting Point: | 207-209 °C (dec.)(lit.) |
| Boiling Point: | 255.6 °C at 760 mmHg |
| Flash Point: | 108.4 °C |
| Solubility: | soluble in water |
| Appearance: | white crystalline powder |
| Hazard Symbols: |
 Xi
|
| Risk Codes: | 36/37/38 |
| Safety: | 26-36 |
| Transport Information: | N/A |
| PSA: | 63.32000 |
| LogP: | 1.29040 |
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Reported in EPA TSCA Inventory.
The 6-Aminocaproic acid is an organic compound with the formula C6H13NO2. The IUPAC name of this chemical is 6-aminohexanoic acid. With the CAS registry number 60-32-2, it is also named as Acide aminocaproique. The product's categories are Amino Acids; Organic Acids; omega-Aminocarboxylic Acids; omega-Functional Alkanols, Carboxylic Acids, Amines & Halides; Fibrinogen/Thrombin. Besides, it is a white crystalline powder, which should be stored in a closed and dark place.
Physical properties about 6-Aminocaproic acid are: (1)ACD/LogP: -0.11; (2)ACD/LogD (pH 5.5): -2.65; (3)ACD/LogD (pH 7.4): -2.61; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 3; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 6; (11)Polar Surface Area: 29.54 Å2; (12)Index of Refraction: 1.467; (13)Molar Refractivity: 34.94 cm3; (14)Molar Volume: 125.8 cm3; (15)Polarizability: 13.85×10-24cm3; (16)Surface Tension: 42.6 dyne/cm; (17)Density: 1.042 g/cm3; (18)Flash Point: 108.4 °C; (19)Enthalpy of Vaporization: 54.29 kJ/mol; (20)Boiling Point: 255.6 °C at 760 mmHg; (21)Vapour Pressure: 0.00495 mmHg at 25°C.
Preparation: this chemical is derived from the hydrolysis of caprolactam.
Uses of 6-Aminocaproic acid: it is used to treat excessive postoperative bleeding, especially after procedures in which a great amount of bleeding is indicated, such as cardiac surgery. It can be given orally or intravenously. A meta-analysis found that lysine analogs like aminocaproic acid significantly reduced blood loss in patients undergoing coronary artery bypass grafting. 6-Aminocaproic acid can also be used to treat the overdose and/or toxic effects of the thrombolytic pharmacologic agents tissue plasminogen activator (commonly known as tPA) and streptokinase.
When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. When you are using it, wear suitable protective clothing. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)CCCCCN
(2)InChI: InChI=1/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
(3)InChIKey: SLXKOJJOQWFEFD-UHFFFAOYAY
(4)Std. InChI: InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
(5)Std. InChIKey: SLXKOJJOQWFEFD-UHFFFAOYSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | oral | > 7gm/kg (7000mg/kg) | Drugs in Japan Vol. 6, Pg. 79, 1982. | |
| dog | LDLo | intravenous | 2150mg/kg (2150mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Pharmacologist. Vol. 3, Pg. 62, 1961. |
| guinea pig | LDLo | intravenous | 19800mg/kg (19800mg/kg) | Anesthesie, Analgesie, Reanimation. Vol. 22, Pg. 481, 1965. | |
| man | TDLo | multiple routes | 14400mg/kg/59 (14400mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS KIDNEY, URETER, AND BLADDER: HEMATURIA | British Journal of Urology. Vol. 60, Pg. 81, 1987. |
| man | TDLo | oral | 1778mg/kg/8D- (1778mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: HEMATURIA | American Journal of Kidney Diseases. Vol. 8, Pg. 441, 1986. |
| monkey | LD50 | intravenous | > 2gm/kg (2000mg/kg) | Drugs in Japan Vol. 6, Pg. 79, 1982. | |
| monkey | LD50 | oral | > 7gm/kg (7000mg/kg) | Drugs in Japan Vol. 6, Pg. 79, 1982. | |
| mouse | LD50 | intravenous | 4900mg/kg (4900mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Anesthesie, Analgesie, Reanimation. Vol. 22, Pg. 481, 1965. |
| mouse | LD50 | oral | 14300mg/kg (14300mg/kg) | Drugs in Japan Vol. 6, Pg. 79, 1982. | |
| mouse | LD50 | subcutaneous | 5790mg/kg (5790mg/kg) | Drugs in Japan Vol. -, Pg. 62, 1995. | |
| rabbit | LD50 | intravenous | 2gm/kg (2000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967. | |
| rat | LD | oral | > 10gm/kg (10000mg/kg) | Pharmacologist. Vol. 3, Pg. 62, 1961. | |
| rat | LD50 | intraperitoneal | 7gm/kg (7000mg/kg) | Pharmacologist. Vol. 3, Pg. 62, 1961. | |
| rat | LD50 | intravenous | 3300mg/kg (3300mg/kg) | Pharmacologist. Vol. 3, Pg. 62, 1961. | |
| women | TDLo | oral | 12600mg/kg/5W (12600mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" | Postgraduate Medical Journal. Vol. 55, Pg. 282, 1979. |
| women | TDLo | oral | 33600mg/kg/14 (33600mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION | Postgraduate Medical Journal. Vol. 55, Pg. 282, 1979. |
